Liquidia rises after beating Q2 revenue estimates, reporting higher drug prescriptions

** Shares of drug developer Liquidia LQDA.O rise 17.9% to $25 premarket

** Co reports Q2 total revenue of $8.84 mln, compared with analysts' estimates of $4.05 mln, as per LSEG data

** Co says its inhaled drug to treat blood pressure, Yuterpia, surpasses 900 patient prescriptions and 550 patient starts within 11 weeks after FDA approval

** This initial demand has exceeded my own high expectations- CEO Roger Jeffs

** On May 23, the U.S. FDA approved Yutrepia inhalation powder to treat adults diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease

** Co had cash and cash equivalents of $173.4 million as of June 30, 2025, compared with $176.5 million as of December 31, 2024

** Up to last close, stock up 80.3% YTD